The purpose of Project Baseline is to map human health so we can convert from a reactive healthcare system to a proactive healthcare system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine
This page contains sponsored advertising.
In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.
Transcript
What is Project Baseline? What is the purpose and how along into the study are you?
Project Baseline is a study that’s partnered between Duke, Stanford, and Verily, which is a subsidiary of Alphabet, and the main goal is to map human health. Just like the roads have been mapped in the past in terms of understanding how to get from point a from point b, to the same thing in terms of what do we understand about health today and understand transitions from other health states tomorrow or a year from now and then incorporating a variety of signals that would help us map out what someone’s health trajectory is.
An example is having a foundation of genomics or a foundation of what’s in their environment or a foundation of what their microbiome is, and then over time seeing how that changes, and picking up new signals from their daily activity to how they’re feeling to how they’re sleeping, and then incorporating all of that to see if we can have better signals and converting from a reactive healthcare system to a proactive system so that we can actually do something to so-called prevent the car crash in health like for how we do with Google Maps.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More